Literature DB >> 14688826

Viral hepatitis: new data on hepatitis C infection.

Erzsébet Szabó1, Gábor Lotz, Csilla Páska, András Kiss, Zsuzsa Schaff.   

Abstract

Viral hepatitis (VH) is almost as old as human beings, at least as old as known human history. However, the natural history and the epidemiology of the disease has undergone changes during the centuries and even recently we have been facing several new aspects. The estimated global prevalence is around 3-5%, which means that approximately 400 million patients are infected with hepatitis B virus and that there are 170 million infections with hepatitis C virus. The mortality figures are projected to show a 2- to 3-fold increase over the next two decades as hepatitis C virus-infected patients develop cirrhosis, which makes this the leading indication for liver transplantation. These data point to the importance of VH being a significant public health problem worldwide. The list of hepatotropic viruses is well known, including hepatitis A (HAV), B (HBV), C (HCV), D (HDV), E (HEV), G (HGV) and F (HFV). HGV and HFV are excluded from the present review, mainly because they are questionable in relation to the causation of liver disease. Our knowledge of HAV, HBV, HDV and HEV has accumulated over the last decade, so the present discussion is focused on HCV, which is currently generating considerable concern and controversy, and is the leading cause of chronic liver disease worldwide. The main questions to be discussed, are: the characterization of the agents' viral genotypes/subtypes, the viral-cell interaction, the pathogenesis of VH, the extrahepatic manifestations of viral infection and hepatocarcinogenesis.

Entities:  

Mesh:

Year:  2003        PMID: 14688826     DOI: 10.1007/BF02893380

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  61 in total

Review 1.  Hepatitis C virus and its pathogenesis.

Authors:  K Shimotohno
Journal:  Semin Cancer Biol       Date:  2000-06       Impact factor: 15.707

Review 2.  Hepatic stem cells.

Authors:  Stuart Forbes; Pamela Vig; Richard Poulsom; Howard Thomas; Malcolm Alison
Journal:  J Pathol       Date:  2002-07       Impact factor: 7.996

Review 3.  The epidemiology of hepatitis C virus infection.

Authors:  Tommy Yen; Emmet B Keeffe; Aijaz Ahmed
Journal:  J Clin Gastroenterol       Date:  2003-01       Impact factor: 3.062

Review 4.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

5.  Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alfa-2b treatment.

Authors:  K Jármay; M Gallai; G Karácsony; Z Ozsvár; Z Schaff; J Lonovics; I Kovalszky
Journal:  J Hepatol       Date:  2000-06       Impact factor: 25.083

6.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

7.  Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C.

Authors:  F Ramalho; A Costa; A Pires; P Cabrita; F Serejo; A P Correia; N Fatela; H Clória; J Lopes; H C Pinto; R Marinho; M Raimundo; J Velosa; A Batista; M C de Moura
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

8.  Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis.

Authors:  J Dudás; I Kovalszky; M Gallai; J O Nagy; Z Schaff; T Knittel; M Mehde; K Neubauer; F Szalay; G Ramadori
Journal:  Am J Clin Pathol       Date:  2001-05       Impact factor: 2.493

9.  Ultrastructural alterations in serial liver biopsy specimens from chimpanzees experimentally infected with a human non-A, non-B hepatitis agent.

Authors:  Z Schaff; E Tabor; D R Jackson; R J Gerety
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1984

10.  Retrovirus-like particles in hepatocytes of patients with transfusion-acquired non-A, non-B hepatitis.

Authors:  S Iwarson; Z Schaff; B Seto; G Norkrans; R J Gerety
Journal:  J Med Virol       Date:  1985-05       Impact factor: 2.327

View more
  26 in total

1.  Hepatitis C and liver transplantation.

Authors:  G Tsoulfas; I Goulis; D Giakoustidis; E Akriviadis; P Agorastou; G Imvrios; V Papanikolaou
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

Review 2.  Impact of new treatment options for hepatitis C virus infection in liver transplantation.

Authors:  Elda Righi; Angela Londero; Alessia Carnelutti; Umberto Baccarani; Matteo Bassetti
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

3.  Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model.

Authors:  Sylvie Lagaye; Sonia Brun; Jesintha Gaston; Hong Shen; Ruzena Stranska; Claire Camus; Clarisse Dubray; Géraldine Rousseau; Pierre-Philippe Massault; Jerôme Courcambeck; Firas Bassisi; Philippe Halfon; Stanislas Pol
Journal:  World J Hepatol       Date:  2016-07-28

Review 4.  Hepatitis C.

Authors:  Daniel P Webster; Paul Klenerman; Geoffrey M Dusheiko
Journal:  Lancet       Date:  2015-02-14       Impact factor: 79.321

5.  A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.

Authors:  David B Olsen; Anne B Eldrup; Linda Bartholomew; Balkrishen Bhat; Michele R Bosserman; Alessandra Ceccacci; Lawrence F Colwell; John F Fay; Osvaldo A Flores; Krista L Getty; Jay A Grobler; Robert L LaFemina; Eric J Markel; Giovanni Migliaccio; Marija Prhavc; Mark W Stahlhut; Joanne E Tomassini; Malcolm MacCoss; Daria J Hazuda; Steven S Carroll
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Association between hepatitis B virus and pancreatic cancer.

Authors:  Manal M Hassan; Donghui Li; Adel S El-Deeb; Robert A Wolff; Melissa L Bondy; Marta Davila; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

7.  SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.

Authors:  Sam Hopkins; Bernard Scorneaux; Zhuhui Huang; Michael G Murray; Stephen Wring; Craig Smitley; Richard Harris; Frank Erdmann; Gunter Fischer; Yves Ribeill
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

Review 8.  The epidemiology of hepatitis C infection in the United States.

Authors:  Vinod K Rustgi
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

Review 9.  Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis.

Authors:  Erzsébet Szabó; Csilla Páska; Pál Kaposi Novák; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

Review 10.  The blind men 'see' the elephant-the many faces of fatty liver disease.

Authors:  Madhusudana Girija Sanal
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.